Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA4 | P22459 | 1/20 | 0.31 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.31 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12306264 | 0.76 | ALDH1A1 (0.30) | — | |
| SCHEMBL12306263 | 0.72 | — | — | |
| SCHEMBL12306261 | 0.72 | — | — | |
| SCHEMBL156352 | 0.71 | — | — | |
| SCHEMBL13447356 | 0.68 | KCNA4 (0.31) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL7399717 | 0.67 | — | — | |
| SCHEMBL2891477 | 0.67 | — | — | |
| SCHEMBL7733528 | 0.64 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL5590449 | 0.64 | KCNA4 (0.33) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1970312 | 0.63 | KCNA4 (0.39) | KCNA4KCNA1KCNAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704988-B2 | Anti-hypercholesterolemic compounds | MERCK & CO., INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100035857-A1 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-02-11 | — | — | US | disclosed |
| US-20090137546-A1 | Anti-Hypercholesterolemic Compounds | MERCK SHARP & DOHME CORP. | 2009-05-28 | — | — | US | disclosed |
| US-20070078098-A1 | Anti-hypercholesterolemic compounds | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137546-A1 | Anti-Hypercholesterolemic Compounds | CETP, HMGCR, PCSK9 | KCNA4 2688/4885KCNA1 2778/4885KCNAB1 1595/4885 |
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | LDLR, PCSK9, CYP46A1 | KCNA4 3346/4885KCNA1 2244/4885KCNAB1 1942/4885 |
| US-20100035857-A1 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | NPC1L1, HMGCR, PCSK9 | KCNA4 2656/4885KCNA1 2693/4885KCNAB1 1689/4885 |
| US-20070078098-A1 | Anti-hypercholesterolemic compounds | CETP, HMGCR, PCSK9 | KCNA4 2688/4885KCNA1 2778/4885KCNAB1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.